Loading...
Relay Therapeutics Q1 2025 Earnings Report
Relay Therapeutics reported its first quarter 2025 financial results and corporate updates, highlighting extended cash runway into 2029 and progress in clinical trials.
Key Takeaways
Relay Therapeutics reported a net loss of $77.1 million for Q1 2025, with total revenue of $7.7 million. The company extended its cash runway into 2029 through strategic cost reductions and expects to fully fund key initiatives, including the ReDiscover-2 trial and vascular malformations clinical proof-of-concept data.
Cash runway extended into 2029, expected to fully fund the Company meaningfully past topline data for ReDiscover-2 trial and through clinical proof-of-concept data in Vascular Malformations.
Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025.
Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 2025.
Strategic cost reductions implemented, including an approximately 80% reduction in research run rate spend and a reduction in force by approximately 70 people.
Revenue by Segment
Forward Guidance
Relay Therapeutics expects its current cash, cash equivalents, and investments to be sufficient to fund its operating expenses and capital expenditure requirements into 2029, enabling the funding of key initiatives including generating topline data from the ReDiscover-2 trial and clinical proof-of-concept data in vascular malformations.
Positive Outlook
- Cash runway extended into 2029, providing long-term financial stability.
- Expected to fully fund the ReDiscover-2 trial and vascular malformations clinical proof-of-concept data.
- Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025.
- Advancement of Fabry and NRAS programs to Investigational New Drug application (IND) readiness.
- Continued advancement of ongoing triplet cohorts with RLY-2608 + fulvestrant + atirmociclib or ribociclib.
Challenges Ahead
- Restructuring activities may be more costly or time-consuming than expected.
- Internal and external costs for ongoing and planned activities may be higher than expected.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...